Picard Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $28.67M
- P/E (TTM)
- –
- Dividend yield
- –
About Picard Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
Picard Medical, Inc., operating primarily through its subsidiary SynCardia Systems, LLC, is a medical technology company specializing in mechanical circulatory support. The company manufactures and commercializes total artificial heart systems designed to replace the function of failing ventricles and valves in patients with end-stage biventricular heart failure. Its core product offering includes the 50cc and 70cc artificial heart implants paired with external pneumatic power systems: the mobile Companion 2 Driver for clinical inpatient stabilization and the lightweight Freedom Driver for outpatient home care. These devices serve primarily as a bridge to heart transplantation for hospitals, cardiac transplant centers, and surgeons treating critically ill patients.
The business operates internationally, with more than 2,100 artificial hearts implanted across 27 countries. Commercial availability centers on the United States and Canada, supported by entities and activities in Australia, China, and Germany. SynCardia maintains its operational headquarters in Tucson, Arizona.
Summary of the business section of Picard Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Picard Medical, Inc.
- Founded
- 2021
- Headquarters
- Tucson, AZ
- Address
- 1992 E. Silverlake Rd. 85713
- Phone
- (520) 308-0796
- Employees
- 75, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- PMI
- Exchange
- NYSE
- IPO date
- Sep 2, 2025
- Shares outstanding
- 2M, Aug 18, 2026
- Public float
- $130.82M, Sep 2, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-50 reverse, Aug 3, 2026
- SEC CIK
- 2030617
- CUSIP
- 71953R108
- ISIN
- US71953R1086
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Patrick Nj Schnegelsberg | Chief Executive Officer, Director | – |
| Matt Schuster | Chief Operating Officer | – |
| Bernard Skaggs | Chief Financial Officer | – |
| George Tiancheng Ye | Director | – |
| Richard Fang | Director | – |
| Van Sam | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 17, 2026 | Late filing | Notification of late filing |
| Jul 27, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 21, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| May 11, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Sep 2, 2025 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 11, 2025 | Listing | Registration of securities on an exchange (Form 8-A) |